[go: up one dir, main page]

PE20040242A1 - Un derivado de piridina opticamente activo y un medicamento que lo contiene - Google Patents

Un derivado de piridina opticamente activo y un medicamento que lo contiene

Info

Publication number
PE20040242A1
PE20040242A1 PE2003000253A PE2003000253A PE20040242A1 PE 20040242 A1 PE20040242 A1 PE 20040242A1 PE 2003000253 A PE2003000253 A PE 2003000253A PE 2003000253 A PE2003000253 A PE 2003000253A PE 20040242 A1 PE20040242 A1 PE 20040242A1
Authority
PE
Peru
Prior art keywords
pyridine derivative
agent
optically active
product containing
medicinal product
Prior art date
Application number
PE2003000253A
Other languages
English (en)
Inventor
Kevin Bacon
Kinji Fuchikami
Keiko Fukushima
Rolf Grosser
Yuji Koriyama
Takashi Yoshino
Toshiki Murata
Noriko Nunami
Sachiko Sasaki
Hiroki Sato
Megumi Yamauchi
Timothy Lowinger
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE20040242A1 publication Critical patent/PE20040242A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN DERIVADO DE PIRIDINA, CONSTITUIDO POR (-)-7-[2-(CICLOPROPILMETOXI)-6-HIDROXIFENIL]-5-[(3S)-3-PIPERIDINIL]-1,4-DIHIDRO-2H-PIRIDO[2,3-d][1,3]OXAZIN-2-ONA DE FORMULA (I) QUE TIENE UNA PUREZA OPTICA DE AL MENOS UN 90% DE EXCESO ENANTIOMERICO. UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE. EL COMPUESTO ES UN INHIBIDOR DE LA QUINASA IkB Y ES UTIL PARA EL TRATAMIENTO Y PROFILAXIS DE EFERMEDADES QUE IMPLICAN LA ACTIVIDAD DE NF-kB, Y ACTUA COMO: a) UN AGENTE ANTIINFLAMATORIO UTIL PARA TRATAR O PREVENIR UNA ENFERMEDAD SELECCIONADA DEL GRUPO CONSTITUIDO POR ASMA,RINITIS ALERGICA, DERMATITIS ATOPICA, URTICARIA, CONJUNTIVITIS, CATARRO PRIMAVERAL, ARTROREUMATISMO CRONICO, LUPUS ERITEMATOSO SISTEMICO,PSORIASIS, COLITIS DIABROTICA,SINDROME DE RESPUESTA INFLAMATORIA SISTEMICA (SIRS), ENTRE OTROS. b) UN INMUNOSUPRESOR; c) UN AGENTE PARA TRATAR ISQUEMIA; d) UN AGENTE ANTITUMORAL
PE2003000253A 2002-03-14 2003-03-13 Un derivado de piridina opticamente activo y un medicamento que lo contiene PE20040242A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002070655A JP2003277383A (ja) 2002-03-14 2002-03-14 光学活性ピリジン誘導体およびそれを含む医薬

Publications (1)

Publication Number Publication Date
PE20040242A1 true PE20040242A1 (es) 2004-05-15

Family

ID=27800344

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000253A PE20040242A1 (es) 2002-03-14 2003-03-13 Un derivado de piridina opticamente activo y un medicamento que lo contiene

Country Status (13)

Country Link
US (2) US7375103B2 (es)
EP (1) EP1487842B1 (es)
JP (2) JP2003277383A (es)
AR (1) AR038950A1 (es)
AU (1) AU2003215624A1 (es)
CA (1) CA2478942A1 (es)
DE (1) DE60312494T2 (es)
ES (1) ES2283795T3 (es)
HN (1) HN2003000098A (es)
PE (1) PE20040242A1 (es)
TW (1) TW200403247A (es)
UY (1) UY27719A1 (es)
WO (1) WO2003076447A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005036655A1 (de) * 2005-08-04 2007-02-08 Bayer Healthcare Ag Behandlung von Tumoren mit IKK-ß Inhibitoren
WO2007106884A2 (en) * 2006-03-15 2007-09-20 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2008044339A1 (en) * 2006-10-13 2008-04-17 Aqumen Biopharmaceuticals K.K. Therapeutic/preventive agent for intraocular disease containing statin compound
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
EP2983669B1 (en) * 2013-04-08 2018-10-24 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EP3288558B1 (en) 2015-04-30 2022-05-11 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
EP3423446B1 (de) 2016-03-03 2020-09-16 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体

Also Published As

Publication number Publication date
DE60312494T2 (de) 2007-11-29
CA2478942A1 (en) 2003-09-18
HN2003000098A (es) 2003-12-15
US7375103B2 (en) 2008-05-20
US20090054424A1 (en) 2009-02-26
WO2003076447A1 (en) 2003-09-18
UY27719A1 (es) 2003-10-31
EP1487842A1 (en) 2004-12-22
AU2003215624A1 (en) 2003-09-22
AR038950A1 (es) 2005-02-02
JP2005526074A (ja) 2005-09-02
EP1487842B1 (en) 2007-03-14
ES2283795T3 (es) 2007-11-01
JP2003277383A (ja) 2003-10-02
TW200403247A (en) 2004-03-01
DE60312494D1 (de) 2007-04-26
US20050215547A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
DOP2006000170A (es) Nuevos derivados de espirocromanona
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX2017010220A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
NO20083567L (no) Hydantoinderivater for behandling av inflammatoriske forstyrrelser
SV2010003706A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
DOP2010000064A (es) 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
PE20040242A1 (es) Un derivado de piridina opticamente activo y un medicamento que lo contiene
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
AR062980A1 (es) Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida
SV2009002900A (es) Diarilurea para el tratamiento de hipertension pulmonar
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
BR112012015433A2 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
MX2015016971A (es) Formulacion que comprende un agente hipolipidemico.
DOP2012000058A (es) Agente terapeutico para trastornos del estado de animo
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
PE20142318A1 (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
AR078142A1 (es) Compuestos inhibidores heteroarilicos biciclicos de pde4, las composiciones farmaceuticas que los contienen y el uso de los mismos para la preparacion de medicamentos.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
PE20200932A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
EP2722042A4 (en) INDANO DERIVATIVES, PHARMACEUTICALLY ALLOWED SALTS OR OPTICAL ISOMERS THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFORE AS AN ACTIVE AGENT FOR THE PREVENTION OR TREATMENT OF VIRUS DISEASES
BR112012015084A2 (pt) composição farmacêutica de liberação lenta de iloperidone
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
CL2008003027A1 (es) Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal